Skip to main content
Premium Trial:

Request an Annual Quote

OpGen to Meet With Nasdaq Panel to Stave Off Delisting

NEW YORK (GenomeWeb) – OpGen will meet with a Nasdaq panel in early 2018 to stave off being delisted from the exchange, the company said in a regulatory document on Tuesday.

In a Form 8-K filing with the US Securities and Exchange Commission, OpGen said that it received written notice on Dec. 21 from Nasdaq informing the company that the exchange would be delisting its stock on Jan. 2, 2018 if it did not request a hearing with a Nasdaq Hearing Panel in relation to the firm's failure to meet certain listing requirements.

In June, OpGen was warned by Nasdaq that it had failed to maintain a minimum bid price of $1 per share for at least 30 consecutive trading days. The exchange gave the company until Dec. 18 to regain compliance.

In May, Nasdaq also warned the firm that fell short of a listing requirement calling for at least $2.5 million in stockholders' equity. In its letter last week, Nasdaq told OpGen that it failed to comply with either listing requirements and was thus ineligible for an additional 180-day extension to meet the minimum bid price requirement, OpGen said.

OpGen requested on Dec. 21 to meet with the Nasdaq panel, staying any suspension or delisting action until the hearing process is concluded and any extension may be granted. An oral hearing is scheduled for Feb. 8, OpGen said in its SEC document.

It added that it has filed a proxy statement for a special meeting of shareholders on Jan. 17, to seek approval for a reverse stock split to meet Nasdaq's minimum bid price.

In early morning trading today, OpGen's shares were down 4 percent at $.1511. 

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.